ClinicalTrials.gg
Enrolling by invitationNCT06926621Updated Oct 14, 2026

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

A Phase 2 interventional study of VX-670 in Myotonic Dystrophy Type 1 (DM1), sponsored by Vertex Pharmaceuticals Incorporated. Enrolling by invitation at 16 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Updated Oct 14, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 28 studies in Myotonic Dystrophy with a site in Canada — 13 open to participants now, 16 under way, 4 of them phase 3. Myotonic Dystrophy · Canada.

Planned enrollment
11th of 25
44 · median 32
Started
2025
with 4 others
Phase 2
4 of 28
3 open now
Primary completion
2029-01
later than 11 of 15 live
Registered
24th of 28
by date
Lead sponsor
2 of 28
Vertex Pharmaceuticals Incorporated

Among the 28 studies in Myotonic Dystrophy with a site in Canada, this one is the 11th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 11 of the 15 other live ones, and was the 24th registered.

Myotonic Dystrophy

126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

13 of the 28 studies in Myotonic Dystrophy with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Myotonic Dystrophy with a site in Canada, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).

03

Conditions studied

  • Myotonic Dystrophy Type 1 (DM1)

Keywords

  • DM 1
  • Myotonic Dystrophy 1
  • Myotonic Dystrophy Type 1 (DM1)
  • VX-670
  • Myotonic Dystrophy
  • DM
  • Myotonia
  • Dystrophy Myotonic
  • Myotonic Disorders
  • Steinert Disease
  • Vertex
  • Entrada
  • PMO
  • ASO
  • Myotonic Muscular Dystrophy
  • Muscular Disorders, Atrophic
  • Muscular Diseases
  • Musculoskeletal Diseases
  • Neuromuscular Diseases
  • Nervous System Diseases
  • Genetic Diseases, Inborn
  • Heredodegenerative Disorders, Nervous System
  • Neurodegenerative Diseases
  • Muscular Dystrophies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completed study drug treatment in parent study VX23-670-001 (NCT06185764)

Key Exclusion Criteria:

  • History of any illness or any clinical condition as pre-specified in the protocol

Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    VX-670

    Participants will receive multiple doses of VX-670.

    Drug: VX-670

Interventions

  • DrugVX-670

    Solution for intravenous administration.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Week 108

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of VX-670 and its Active Component in Plasma

    Time frame: From Day 1 up to Week 96

  2. Area Under the Concentration Versus Time Curve (AUC) of VX-670 and its Active Component in Plasma

    Time frame: From Day 1 up to Week 96

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jan 2029, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 14, 2025
StartActual
Apr 28, 2025
Primary completionEst.
Jan 30, 2029
CompletionEst.
Jan 30, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Wake Forest Univ School of Medicine - Neurology · Winston-Salem, United States
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    1 site added
    Show site
    • Wake Forest Univ School of Medicine - Neurology · Winston-Salem, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06926621
Responsible party
Sponsor
First posted
Apr 14, 2025
Start date
Apr 28, 2025
Primary completion
Jan 30, 2029 (estimated)
Completion
Jan 30, 2029 (estimated)
Last update
Oct 14, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion